FTC Making Last-Ditch Effort to Kill 'Reverse Payments'

Drug Industry Daily
KEYWORDS courts / Patents
A A

The practice of “reverse payments” between brand and generic drugmakers could become much more commonplace if the FTC is unsuccessful in its last-ditch effort to abolish the patent settlement strategy.

To View This Article:

Login

Subscribe To Drug Industry Daily